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1. Introduction 
Mixed Lineage Leukemia constitutes a heterogeneous category of rare acute leukemias that 
are characterized by a mixed population of poorly differentiated lymphoid and myeloid 
progenitor cells. The mixed lineage leukemia (MLL1) gene, also known as HRX or ALL-1, is 
a frequent site of genetic rearrangements in infant acute leukemias and therapy-related 
malignancies (Daser and Rabbitts, 2005) and since its discovery (Djabali et al., 1992; Tkachuk 
et al., 1992; Ziemin-van der Poel et al., 1991), significant progress has been made in 
understanding its role in human biology and leukemogenesis (Liu et al., 2009; Slany, 2009). 
Chromosomal abnormalities involving the MLL1 gene include reciprocal chromosomal 
translocations, internal partial tandem duplications (PTD), and amplifications of un-
rearranged MLL1 (Dou and Hess, 2008). These chromosomal aberrations are associated with 
mechanistically distinct gain-of-function phenotypes that may be amenable to targeted 
therapeutic approaches. However, progress in this area has been impeded by a lack of 
understanding of the molecular details by which MLL1 translocations, amplifications and 
PTDs contribute to leukemogenesis. To date, more than 60 MLL1 fusion partners have been 
described (Krivtsov and Armstrong, 2007), and detailed genetic/biochemical studies have 
identified several functional domains within chimeric MLL1-fusion proteins that are 
essential for leukemic transformation (Daser and Rabbitts, 2005; Debernardi et al., 2002; 
Eguchi et al., 2004; Ernst et al., 2002; Krivtsov and Armstrong, 2007; Lavau et al., 2000; Liu et 
al., 2009; Luo et al., 2001; Mitterbauer-Hohendanner and Mannhalter, 2004; Mueller et al., 
2009; Prasad et al., 1995). Although our understanding of the molecular pathology of MLL1-
associated leukemias remains incomplete, recent biochemical and structural information is 
contributing to an evolution of potential treatment strategies from a broadly-based 
chemotherapeutics approach towards therapies targeted to the underlying molecular 
pathogenesis of leukemia (Liedtke and Cleary, 2009). This chapter reviews recent advances 
in our efforts to develop novel MLL1-targeted therapies.   
2. MLL1- a master epigenetic regulator with multiple roles in transcription 
2.1 MLL1 in embryonic development and hematopoiesis 
The MLL1 protein is a histone H3 lysine 4 (H3K4) methyltransferase that functions to maintain 
gene expression during development and hematopoiesis (Hess et al., 1997; Milne et al., 2002; 
www.intechopen.com
 
Acute Leukemia – The Scientist's Perspective and Challenge 
 
158 
Yagi et al., 1998).  The best studied target genes of MLL1 include the homeobox transcription 
factors or HOX genes, which are important for segment identity and cell fate during metazoan 
development (Abramovich and Humphries, 2005; Ernst et al., 2004b). Genetic studies in mice 
have demonstrated that the homozygous knock out of MLL1 is embryonic lethal and is 
associated with multiple developmental defects including neural crest patterning and 
hematopoietic abnormalities (Ernst et al., 2004a; Hess et al., 1997; Yagi et al., 1998; Yu et al., 
1995). Notably, the expression levels of several HOX genes including HOXa4, HOXa7, HOXa9, 
and HOXa10 are decreased in MLL1-/- mice and are associated with defects in fetal liver 
hematopoiesis (Hanson et al., 1999; Yagi et al., 1998). MLL1+/- mice are not embryonic lethal 
but are anemic and exhibit homeotic developmental defects that are related to posterior shifts 
in HOX gene expression patterns (Yagi et al., 1998; Yu et al., 1995). Likewise, MLL1 is also 
required for adult hematopoiesis and stem cell self-renewal. In MLL1 conditional knockout 
mice fetal hematopoiesis is unaltered; however, adult mice exhibit anemia, a significant 
reduction in the number of bone marrow hematopoietic stem cell progenitors, and poor 
survival rates (Gan et al., 2010). In addition, it has been demonstrated that MLL1 plays a 
crucial role in self-renewal in cultured fetal liver and adult bone marrow stem cells (Jude et al., 
2007; McMahon et al., 2007). These studies suggest that MLL1 orchestrates its biological 
functions at least in part through the regulation of HOX genes. Indeed, HOX dysregulation is a 
common phenotype that underlies the pathogenesis of acute leukemias associated with 
alterations in the MLL1 gene (Armstrong et al., 2002; Ayton and Cleary, 2003; Dorrance et al., 
2006; Ferrando et al., 2003; Liu et al., 2009). However, MLL1 is also required for the regulation 
of cell cycle dependent genes such as: cyclins A, B, and E (Takeda et al., 2006) and CDK 
inhibitors p16Ink4a, p18, p27 (Milne et al., 2005; Takeda et al., 2006); E2F family of transcription 
factors (E2F2, E2F4 and E2F6) (Takeda et al., 2006) as well as the transcription factor GATA3, 
which plays an essential role in specifying lymphoid subtype (Yamashita et al., 2006). In 
addition, MLL1 regulates expression of several genes involved in organogenesis and 
differentiation (Ansari and Mandal, 2010; Scharf et al., 2007) . Therefore, MLL1 is a master 
regulator that is critical for many gene expression programs required for normal development, 
hematopoiesis and the cell cycle.  
2.2 MLL1 regulates the degree of H3K4 methylation and transcription 
In eukaryotes, DNA is condensed into highly ordered structures known as chromatin- the 
structure of which is dynamically altered according to the needs of the cell. The basic 
repeating unit of chromatin is the nucleosome, which is composed of ~146 base pairs of 
DNA wrapped around an octameric disc of histone proteins containing two copies each of 
histones H2A, H2B, H3 and H4 (Luger and Hansen, 2005). Cellular processes that require 
access to DNA often use enzymes that dynamically regulate the structure of chromatin 
either through recruitment of adaptor proteins or additional enzymatic machineries that 
alter the positioning of nucleosomes on DNA (Cosgrove and Wolberger, 2005). One such 
enzymatic activity is the methylation of lysine 4 of histone H3 (H3K4), an evolutionarily 
conserved epigenetic mark predominantly associated with transcriptional activation in 
eukaryotes (Bernstein et al., 2002; Boggs et al., 2002; Litt et al., 2001; Noma and Grewal, 2002; 
Strahl et al., 1999). The epsilon amino group of lysine 4 can be mono-, di-, or trimethylated, 
with each modification correlating with distinct transcriptional outcomes (Bernstein et al., 
2005; Ng et al., 2003; Pokholok et al., 2005; Santos-Rosa et al., 2002; Schneider et al., 2004; 
Schubeler et al., 2004). For example, genome-wide chromatin immunoprecipitation studies 
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have demonstrated that high levels of H3K4 trimethylation are present within the 5’ regions 
of actively transcribed genes (Pokholok et al., 2005; Santos-Rosa et al., 2002; Schneider et al., 
2004; Schubeler et al., 2004). It has been demonstrated that H3K4 trimethylation functions to 
recruit ATP dependent nucleosome remodeling enzymes that increase promoter DNA 
accessibility by sliding or displacing nucleosomes (Pray-Grant et al., 2005; Santos-Rosa et al., 
2003; Wysocka et al., 2006). H3K4 dimethylation is spread more evenly across the coding 
regions of genes and is thought to be associated with a transcriptionally “poised” state of 
chromatin (Bernstein et al., 2002; Schneider et al., 2004; Schubeler et al., 2004). In contrast, 
H3K4 monomethylation is enriched at the 3’ ends of the genes and distal enhancer 
sequences, and is associated with ribosomal DNA (rDNA) and telomeric silencing 
(Bernstein et al., 2002; Heintzman et al., 2007; Pokholok et al., 2005; Santos-Rosa et al., 2002; 
Schneider et al., 2004; Schubeler et al., 2004)(Nislow, Ray et al. 1997; Briggs, Bryk et al. 2001; 
Schneider, Wood et al. 2005; van Dijk, Marley et al. 2005). These studies suggest that the 
degree of H3K4 methylation is a highly regulated process. Indeed eukaryotes have evolved 
a number of highly conserved enzymes whose function appears to precisely regulate the 
degree of H3K4 methylation.  
H3K4 methylation is mainly deposited by a group of enzymes that share an evolutionarily 
conserved  SET (SuVar, E(z), Trithorax) domain  (Dillon et al., 2005) , although a new H3K4 
methyltransferase lacking a SET domain has recently been reported (Patel et al., 2009; Patel 
et al., 2011). While there are several SET domains enzymes that differ with regard to their 
substrate specificity (Dillon et al., 2005; Qian and Zhou, 2006), members of the SET1 family 
share the properties that they all methylate H3K4, and all interact with an evolutionarily 
conserved core group of proteins that function to regulate the degree of H3K4 methylation. 
MLL1 belongs to the SET1 family of histone methyltransferases and evidence suggests that 
its transcriptional co-activator function is mediated in part by the enzymatic activity of its 
SET domain (Dillon et al., 2005; Milne et al., 2002). For example, homozygous deletion of the 
MLL1 SET domain in mice, while not embryonic lethal, exhibits skeletal defects and altered 
expression of several HOX genes that partially phenocopy the heterozygous knockout of the 
whole MLL1 gene (Terranova et al., 2006). These changes are correlated with decreased 
levels of mono- and dimethylation of H3K4 and deregulated DNA methylation patterns at 
several HOX gene promoters (Terranova et al., 2006).  
MLL1 functions within a large macromolecular complex with more than 30 subunits that 
regulate the degree of H3K4 methylation and MLL1’s target gene specificity (Cosgrove and 
Patel, 2010). While subunit composition of different SET1 family members varies to some 
degree, each SET1 family member interacts with a conserved core group of proteins that 
include WD-40 repeat protein-5 (WDR5), Retinoblastoma binding protein-5 (RbBP5), Absent 
small homeotic 2-like protein (Ash2L) and Dumpy30 (Dpy-30) (Cho et al., 2007; Dou et al., 
2006; Lee et al., 2007). WRD5, RbBP5, Ash2L and DPY-30 form an indepedent complex 
called WRAD that possesses an intrisic histone methyltransferase activity on its own (Patel 
et al., 2009; Patel et al., 2011). When WRAD interacts with MLL1, it forms what is known as 
the MLL1 core complex, which is required for mono- and dimethylation of H3K4 (Dou et al., 
2006; Patel et al., 2009). These studies have led to a model in which H3K4 methylation is 
sequentially catalyzed by a complex that contains multiple distinct active sites for the 
addition of each methyl group (Patel et al., 2009).  
2.3 Mechanism of multiple lysine methylation catalyzed by MLL1 core complex 
Previously it was thought that mono-, di-, and trimethylation of H3K4 could be attributed to 
the SET domain dependent methyltransferase activity of MLL1 alone and that the WRAD 
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complex functions merely as an allosteric regulator of MLL1 (Cheng et al., 2005; Collins et al., 
2005; Dou et al., 2006; Han et al., 2006; Ruthenburg et al., 2006; Southall et al., 2009; Steward et 
al., 2006; Takahashi et al., 2009). However, since it has more recently been demonstrated that 
the WRAD complex dimethylates H3K4 in a manner that is independent of the enzymatic 
activity of the MLL1 SET domain (Patel et al., 2009), the allosteric model needs to be revised. 
Indeed, in vitro methylation assays demonstrate that the isolated MLL1 SET domain is 
predominantly a monomethyltranferse, which can be attributed to the presence of a conserved 
tyrosine residue in the SET domain active site (Patel et al., 2009). Furthermore, loss of the 
WDR5, RbBP5 or Ash2L subunits of WRAD results in the loss of di- and trimethylation of 
H3K4 both in vivo and in vitro without significant changes in H3K4 monomethylation (Dou et 
al., 2006; Patel et al., 2009; Patel et al., 2008b; Wysocka et al., 2005). These results are consistent 
with a sequential mechanism whereby the MLL1 SET domain catalyzes H3K4 
monomethylation and the WRAD enzyme catalyzes H3K4 dimethylation within the MLL1 
core complex. However, WRAD lacks the ability to dimethylate H3K4 without MLL1, 
suggesting that MLL1 amino acid sequences,  distinct from the MLL1 SET domain active site,  
contributes to the WRAD active site within the MLL1 core complex. That a complex between 
WRAD and MLL1 is required for H3K4 dimethylation is supported by the demonstration that 
amino acid substitutions that disrupt the interaction between MLL1 and WRAD also disrupt 
the H3K4 dimethylation activity of the MLL1 core complex (Patel et al., 2008b). Therefore, the 
completely assembled MLL1 core complex is required for efficient H3K4 dimethylation and 
for nucleosome methylation (Patel et al., 2011). The existence of a sequential mechanism 
utilizing several active sites for multiple lysine methylation suggests that the degree of H3K4 
methylation is more highly regulated than previously appreciated.  
2.4 WRAD components are associated with development and oncogenesis 
One of the common features of the greater than 60-MLL fusion proteins associated with 
leukemias is that in most cases they lose the amino acid sequences required for interaction 
with WRAD. This raises questions about WRAD’s role in MLL1 associated oncogenesis. 
WRAD subunits are conserved within SET1 family complexes ranging from yeast to humans 
(Cho et al., 2007; Dou et al., 2006; Lee and Skalnik, 2005; Lee et al., 2007; Steward et al., 2006) 
and have been shown to play essential roles in cellular differentiation (Gori and Demay, 
2005; Gori et al., 2005; Zhu et al., 2008), development (Adamson and Shearn, 1996; Wysocka 
et al., 2005), dosage compensation (Hsu et al., 1995; Hsu and Meyer, 1994), embryogenesis 
(Stoller et al.), and transcription (Tan et al., 2008). However, the WRAD enzyme lacks 
sequence homology to known methyltransferase folds and as a result relatively little is 
understood about its methyltransferase activity and the role it might play in oncogenesis. 
WRAD’s potential role in oncogenesis is supported by the observation that the Ash2L 
component of WRAD is overexpressed at the protein level in many human tumors, and that 
knockdown of Ash2L inhibits tumor cell proliferation (Luscher-Firzlaff et al., 2008). In 
addition, the RbBP5 component of WRAD has been shown to be amplified in several 
glioblastomas, suggesting that it may be a novel oncogene (Bralten et al., 2010). Further 
studies will be required to better understand WRAD’s role in MLL1 associated 
leukemogenesis and other cancers.  
In contrast, the MLL1 component of the MLL1 core complex is more extensively 
characterized and several functional domains implicated in transcriptional regulation have 
been identified (for recent reviews refer to Ansari and Mandal, 2010; Cosgrove and Patel, 
2010). Furthermore, MLL1 is a frequent site of chromosomal alterations that sometimes 
www.intechopen.com
Biochemistry of the Mixed Lineage 
Leukemia 1 (MLL1) Protein and Targeted Therapies for Associated Leukemia 
 
161 
disrupt the functions of these domains. The next subsection summarizes recent genetic, 
biochemical and structural studies of the functional domains that regulate MLL1’s gene 
targeting and H3K4 methyltransferase activity.   
2.5 MLL1 functional domains implicated in transcriptional regulation 
The MLL1 gene encodes a large protein of 3,969 amino acid residues and contains several 
functional domains including: menin binding motif (MBM), Lens epithelium derived 
growth factor (LEDGF) binding domain (LBD), DNA-binding AT hooks, a cysteine-rich 
CXXC DNA binding motif, plant homeodomain (PHD) fingers, a bromo domain (BD), a 
transactivation domain (TAD), a WDR5 interaction (Win) motif, and a C-terminal histone 
methyltransferase SET domain (Figure 1) (Cosgrove and Patel, 2010). The full-length MLL1 
protein, synthesized as a single transcript, is cleaved by taspase I into MLL1-N (320 kDa) 
and MLL1-C (180 kDa) fragments, which then re-associate through the FYRN and FYRC 
motifs to form the functional MLL1 complex in vivo (Figure 1) (Hsieh et al., 2003a; Hsieh et 
al., 2003b; Yokoyama et al., 2002). The mature MLL1 protein assembles into macromolecular 
complexes with several regulatory proteins that are essential for MLL1’s transcriptional co- 
activator properties. Biochemical and genetic studies have identified several direct and 
 
 
 
Schematic representation showing the functional domains present in the MLL1 protein. Menin binding 
motif MBM (purple), LEDGF binding domain or LBD (light red), DNA binding AT-hooks (black), zinc 
finger containing CXXC motifs (pink), plant homeodomain (PHD) fingers (blue), bromodomain (BD) 
(yellow), phenylalanine-tyrosine rich regions (FYR) (brown), WDR5 interaction (Win) motif (light 
green), and the histone methyltransferase SET domain (red) are highlighted. a) The full-length MLL1 
protein (3969 amino acids) is cleaved by Taspase 1 into MLL-N (300 kDa) and MLL-C (180 kDa) 
fragments that then re-associate through FYRN and FYRC motifs to form a stable complex. This mature 
MLL1 protein then assembles into a macromolecular complex with a number of proteins including- 
menin (green); lens epithelium derived growth factor or LEDGF (dark grey); nuclear cyclophilin 
(Cyp33) (light grey); host cell factor (HCF) (light pink); CREB binding protein (CBP) (dark green); 
histone acetyltransferase MOF (orange); WD-40 repeat containing protein-5 (WDR5) (dark blue); 
retinoblastoma binding protein-5 (RbBP5) (cyan); absent, small, homeotic disc-2 like (Ash2L) (olive 
green); and DPY-30 (light purple).   
Fig. 1. Domain architecture of human MLL1. 
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indirect interaction partners for MLL1 that include; the menin tumor suppressor protein 
(Hughes et al., 2004; Yokoyama et al., 2004); cell cycle regulators such as E2Fs and HCF-1 
(Tyagi et al., 2007; Yokoyama et al., 2004);   polycomb group proteins, BMI-1 and HPC-2 (Xia 
et al., 2003); histone deacetylases (Nakamura et al., 2002; Xia et al., 2003); nuclear 
cyclophilin, Cyp33 (Xia et al., 2003); acetyltransferases such as p300, CBP and MOF (Dou et 
al., 2005; Ernst et al., 2001); chromatin remodeling factors, INI1/SNF5 (Rozenblatt-Rosen et 
al., 1998); and WDR5/RbBP5/Ash2L and DPY30, which are core components of SET1 family 
methyltransferases (Dou et al., 2006). In addition, a recent paper describes the identification 
of a gene internal promoter that transcribes the C-terminal half of MLL1 (Scharf et al., 2007), 
the function of which is not known. Interestingly, the gene internal promoter coincides with 
an MLL1 breakpoint region, suggesting that the pathogenesis of MLL1 translocation 
induced leukemia could be due in part to the loss of this N-terminally truncated form of 
MLL1 when the breakpoint is 5’ to the gene internal promoter. However, in cases where the 
MLL1 breakpoint is 3’ to the gene internal promoter, it could result in aberrant expression of 
the fusion protein (Scharf et al., 2007). Indeed, it has been noted that the common MLL1 
translocation partners AF4, AF6, and ENL have potential AUG start codons in positions 
where they could be transcribed within the context of the translocated MLL1 gene (Scharf et 
al., 2007). 
These studies suggest that the transcriptional activator properties of MLL1 are mediated 
through multiple functional domains through protein-protein and protein-DNA 
interactions. Many of these interactions are retained in leukemogenic MLL1s, some 
participating in gain-of function phenotypes, making them candidates for molecular 
targeted therapy. We review progress in this area in sections 3-5.  In section 2, we describe in 
more detail our current understanding of the role of MLL1 alterations in hematopoietic 
malignancies.  
3. MLL1-A key player in hematologic malignancies 
3.1 Acute myeloid and lymphoblastic leukemia with 11q23 abnormalities  
3.1.1 Incidence and clinical significance of 11q23 chromosomal translocations 
The MLL1 gene located at chromosome 11, band q23, is frequently involved in reciprocal 
translocations found in several cases of acute myeloid (AML) and acute lymphoblastic 
leukemia (ALL) (Djabali et al., 1992; Gu et al., 1992; Ziemin-van der Poel et al., 1991) and 
identify a patient sub-population with a poor prognosis (Daser and Rabbitts, 2005). 
Recurrent MLL1 translocations account for >70% of infant acute leukemias (both ALL and 
AML) and are also observed in approximately 10% of de novo AML in adults (Krivtsov and 
Armstrong, 2007), and in therapy-related leukemias that develop in patients treated with 
topoisomerase II inhibitors (Bigoni et al., 1999; Felix et al., 1995; Krivtsov and Armstrong, 
2007). Chromosomal translocations fuse the N-terminal part (~1400 amino acids) of the MLL1 
protein in-frame to one of more than 60 partner proteins that range from nuclear factors to 
cytoplasmic proteins (Daser and Rabbitts, 2005; Huret et al., 2001; Schoch et al., 2003). 
The five most common MLL1 translocations include: MLL1-AF4 or t(4;11)(q21;q23); 
MLL1-ENL or t(11;19)(q23;p13.3); MLL1-AF9 or t(9;11)(p23;q23), MLL1-AF10 or 
t(10;11)(p12;q23), and MLL1-AF6 or t(6;11)(q27;q23) and account for greater than 80% of 
MLL1-rearranged leukemias (Burmeister et al., 2009; Meyer et al., 2009; Meyer et al., 2006; 
Slany, 2009). In addition, chimeric MLL1-fusions involving ELL, EEN, GAS7, AF1p, AFx, 
Septins, and histone acetyltransferases CBP/p300 have also been reported (Bernard et al., 
1994; Dobson et al., 2000; Hall and Russell, 2004; Ida et al., 1997; Krivtsov and Armstrong, 
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2007; Meyer et al., 2009; Schichman et al., 1995; So et al., 2003; Taki et al., 1997; Tkachuk et 
al., 1992; Wang et al., 2005). The translocation partners identified to date are diverse and 
do not share any biochemical function or structural motifs. However, all known MLL1 
fusion proteins share the property that the N-terminal portion containing the AT hooks 
and CxxC domains of MLL1 are retained, suggesting the preservation of DNA binding 
activity (Ayton et al., 2004; Macrini et al., 2003). In contrast, the taspase cleavage site, gene 
internal promoter, TAD domain, PHD fingers, Win motif and the SET domain are lost 
(Figure 2) (Liu et al., 2009).  
 
 
The putative protein products generated by the two most common chromosomal alterations associated 
with the MLL1 gene are indicated along with wild-type MLL1: a) wild-type MLL1, b) reciprocal 
chromosomal translocations involving MLL1, and c) partial tandem duplications (PTDs) in MLL1. The 
various functional domains are color coded as in Figure 1.  Chromosomal translocations fuse the N-
terminal ~1400 amino acids of MLL1 in-frame to one of over 60 different fusion partners (indicated in 
orange in b). PTDs have a duplicated N-terminus (AT-hooks and CXXC motifs) in addition to all the 
functional domains present in wild-type MLL1.  
Fig. 2. Schematic representation of the most common genetic alterations associated with the 
MLL1 gene. 
3.1.2 Pathogenesis of acute leukemias with MLL1-translocations 
While it is expected that the loss of SET domain in MLL1 translocations would result in 
decreased H3K4 methylation and Hox gene expression, genetic studies have revealed that 
the individual fusion partners possess transcriptional activator properties and are 
indispensable for leukemogenesis (Chen et al., 2006a; Dobson et al., 1999; Dobson et al., 
2000; Wang et al., 2005). Given the complexity of different translocation partners, MLL1-
fusions may activate a common leukemia-associated gene expression program through 
multiple mechanisms. Indeed, AF4, AF5, AF9, ENL, ELL and AF10 proteins are all 
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implicated in transcriptional elongation via association with the EAF complex, pTEFb 
kinase, and hDOT1 mediated methylation of H3K79 (Bitoun et al., 2007; Luo et al., 2001; 
Mueller et al., 2007; Mueller et al., 2009; Okada et al., 2005; Simone et al., 2001). Another 
mechanism could involve transcriptional activation via increased or aberrant histone 
acetylation (MLL-CBP/p300) (Lavau et al., 2000; Sobulo et al., 1997), protein arginine 
methyltransferase-1 (PRMT1) association (MLL-EEN) (Cheung et al., 2007), SWI-SNF 
chromatin-remodeling complex recruitment (MLL-ENL, -AF9, -AF10) (Debernardi et al., 
2002; Nie et al., 2003; Schreiner et al., 1999), and  self-association or dimerization of the N-
terminal part of MLL1 (MLL-GAS7, -AF1p, -beta-galactosidase, -gephyrin, -SEPT6) (Dobson 
et al., 2000; Eguchi et al., 2004; Martin et al., 2003; So et al., 2003).  
Regardless of the mechanism, aberrant expression of MLL1 target genes are a common 
feature of MLL1-rearrangements examined to date. For example, HOXa7, HOXa9, and the 
HOX cofactor MEIS1 are consistently over expressed in human leukemias with MLL1-
translocations (Armstrong et al., 2002; Ayton and Cleary, 2003; Rozovskaia et al., 2001; Yeoh 
et al., 2002; Zeisig et al., 2004) and act, at least partially, through the activation of the proto-
oncogene c-Myb (Hess et al., 2006). Furthermore, retroviral co-transduction studies in mice 
have demonstrated that HOXa9 and MEIS1 expression immortalizes hematopoietic 
progenitors in vitro and rapidly accelerates leukemia development (Kroon et al., 1998). In 
addition, MLL1-fusion proteins fail to transform bone marrow cells in which HOXa7 and 
HOXa9 expression are genetically ablated (Ayton and Cleary, 2003). Similarly, it has been 
demonstrated that expression of HOXa9 and MEIS1 can replace the leukemogenic activity of 
MLL1-ENL (Zeisig et al., 2004). Collectively, these results suggest that HOXa9 dysregulation 
is an important factor in some MLL1-fusion induced leukemias (Ayton and Cleary, 2003). 
However, not all leukemogenic fusions result in HOXa9 dysregulation. For example, MLL1-
GAS7 and MLL1-AF9 fusions were shown to transform bone marrow cells or mice that do 
not express HOXa9 (Kumar et al., 2004; So et al., 2004).  
However, in addition to disregulation of HOX genes, other signaling pathways are 
perturbed by MLL-translocations and may contribute to leukemogeneis. For example, 
transcriptional deregulation of FMS-like tyrosine kinase 3(FLT3), glycogen synthase kinase 3 
(GSK3), heat shock protein-90 (HSP-90), myeloid cell leukemia sequence-1 (MCL-1), and 
components of the RAS pathway have been implicated in MLL1-induced leukemogenesis 
(Armstrong et al., 2003; Brown et al., 2005; Carnicer et al., 2004; Liang et al., 2006; Stubbs et 
al., 2008; Wang et al., 2008; Yao et al., 2005; Yasui et al., 2005; Yocum et al., 2006). MLL1’s 
role as a master regulator of gene expression significantly complicates understanding its role 
in MLL1 associated leukemogenesis.  
The master regulatory role of MLL1 in transcriptional control has implications that affect 
our normal understanding of malignancy. For example, it has been suggested that second-
hit mutations are required to initiate the full leukemia phenotype (Dobson et al., 2000). 
Indeed, recent studies have identified mutations in p53, ATM, Ras, and FLT3 genes in MLL1 
leukemia patients (Felix et al., 1998; Mahgoub et al., 1998; Oguchi et al., 2003; Taketani et al., 
2004).  However, because of MLL1’s role in epigenetic gene control, second hit mutations 
could also arise in the form of epigenetic mutations that result in silencing of tumor 
suppressors genes without changes in their DNA sequence. For example, it has been 
demonstrated that the FHIT tumor suppressor gene is epigenetically silenced in human 
primary tumor cells and tumor cell lines with MLL1-translocations (Stam et al., 2006).   
These data suggest that epigenetic alterations may be just as important as genetic mutations 
in sources of so called “2nd hit” mutations that underlie the pathogenesis of leukemia. 
Recent advances in deep sequencing technologies such as RNA-SEQ and CHIP-SEq will 
likely allow us to better distinguish genetic versus epigenetic aberrations in future studies.  
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3.2 Partial tandem duplications: A cytogenetically normal rearrangement in MLL1 
3.2.1 Clinical significance of MLL1 partial tandem duplications (MLL1-PTDs) 
The second common MLL1-rearrangement, internal partial tandem duplication (MLL1- 
PTD) was first observed in de novo AML patients with a normal karyotype or trisomy 11 
(Caligiuri et al., 1994). MLL1-PTDs are found in 4-7% of the cases of AML and present a 
cytogenetically normal rearrangement that is associated with poor prognosis (Caligiuri et 
al., 1998; Dohner et al., 2002; Schichman et al., 1994; Schichman et al., 1995). MLL1-PTDs 
result from an in frame fusion of exons 11-5 or 12-5 upstream of exon 5, partially duplicating 
sequences in the 5’ end of MLL1 (Caligiuri et al., 1994; Quentmeier et al., 2003; Schichman et 
al., 1994). The protein product of MLL1-PTDs has a duplicated N-terminus that contains an 
additional AT-hook and CXXC domain while essentially retaining all the conserved 
domains in wild-type MLL1 (Quentmeier et al., 2003; Schichman et al., 1994). In contrast to 
the variety of MLL1-fusions that delete the MLL1 C-terminus, MLL1-PTDs retain the 3’-
portion of the gene that encodes the SET domain methyltransferase motif (Figure 2).  Recent 
data suggests that the enzymatic activity of the MLL-PTD SET domain participates in a gain-
of function phenotype in AML. 
3.2.2 Mechanism of leukemic transformation by MLL1-PTDs 
The molecular mechanisms that underlie MLL1-PTD transformation in AML are currently 
unknown. The crucial alteration is the duplication of AT hooks and CXXC DNA binding 
motifs, which may alter target gene specificity. It has been suggested that duplication of 
these segments may also mimic dimerization observed in several MLL1 chimeric fusion 
proteins (Martin et al., 2003). Indeed, it has been demonstrated that a synthetic MLL1 N-
terminal construct containing duplicated AT-hook and CXXC domains possesses potent 
transactivation activity in luciferase reporter assays (Martin et al., 2003). However, 
comparison of genome-wide gene expression data shows that MLL1-PTD primary cells 
have gene expression patterns that are distinct from that of cells bearing MLL1 chimeric 
fusions suggesting that the mechanism underlying transformation is distinct (Ross et al., 
2004). Alternatively, it has been suggested that the additional amino acid sequences in 
MLL1-PTD might adopt a conformation that potentially interferes with the normal 
function of MLL1 by distancing the regulatory domains from its target site (Dou and 
Hess, 2008).  
There is a growing body of evidence that suggests that epigenetic alterations underlie the 
pathogenesis of MLL1-PTDs. For example, it has been demonstrated that knock-in mice 
bearing MLL1PTD/WT exhibit increased expression of HOXa7, HOXa9, and HOXa10 that is 
associated with increased H3K4 methylation and H3/H4 acetylation within these promoters 
(Dorrance et al., 2006). Similar gene expression and H3K4 dimethylation changes were seen 
in the presence and absence of the wild type MLL1 allele in primary MLL1-PTD mouse fetal 
liver cells, suggesting that MLL1-PTD behaves as a dominant gain-of-function mutation 
(Dorrance et al., 2008). This phenotype may also be due to other epigenetic alterations. For 
example, Whitman and colleagues (2005) have demonstrated that the wild type MLL1 allele 
in MLL1PTD/WT AML cells is silenced in a manner that is associated with hypoacetylation of 
histones H3 and H4 (Whitman et al., 2005). Treatment of MLL1-PTD cells with histone 
deacetylase inhibitors partially reactivates wild type MLL1 expression and reduces AML 
blast colony forming units (Whitman et al., 2008). In addition, it has been demonstrated that 
the SLC5A8 tumor suppressor gene is silenced in MLL-PTD cells in a manner that is 
associated with increased DNA methylation in its promoter, a phenotype that is partially 
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reversed with DNA methyltransferase inhibitors (Whitman et al., 2008). SLC5A8 encodes a 
membrane monocarboxylate transporter that regulates intracellular concentrations of 
histone deacetylase inhibitors, such as butyrate and pyruvate (Ganapathy et al., 2005; Gupta 
et al., 2006). Together, these observations suggest that targeting MLL1-PTD may have 
therapeutic value in the treatment of AML (Whitman et al., 2005). Indeed, it has been 
demonstrated that down regulation of MLL1-PTD using antisense oligodeoxynucleotides 
(aODNs) in primary human MLL-PTD AMLs results in reactivation of the wild type MLL1 
gene, reduced AML blast-derived colony forming units, and increased sensitivity to cell 
death (Whitman et al., 2008).   
3.3 Acute myeloid leukemia with amplifications in MLL1 
Amplifications of the MLL1 gene, including trisomy 11 and intrachromosomal 
amplifications, are found with less frequency in AML and other myelodysplastic syndromes 
and are associated with a complex karyotype and poor prognosis (Allen et al., 1998; 
Ariyama et al., 1998; Avet-Loiseau et al., 1999; Cuthbert et al., 1999; Herry et al., 2006; Poppe 
et al., 2004; Streubel et al., 2000). Amplifications involving MLL1 result in up-regulation of 
several HOX genes including, HOXa7, HOXa9, and MEIS1 (Herry et al., 2006; Poppe et al., 
2004). These studies suggest that MLL1-amplifications contribute to leukemogenesis 
through mechanisms that share some features with that of MLL1-fusions and MLL1-PTDs. 
In addition, gene expression analyses have identified other proteins that are up-regulated in 
AML with 11q23 amplifications including cell surface receptors PROML1, ADAM10, and 
NKG2D, and the inosine triphosphatase (ITPA) (Poppe et al., 2004). These data suggest that 
MLL1 amplifications are associated with a gain-of-function phenotype that may be 
responsive to targeted therapy (Poppe et al., 2004).  
In spite of these advances in our understanding of the pathogenesis of MLL1-linked 
leukemias, identification of inhibitors that specifically target MLL1 or MLL1-chimeric 
fusion proteins has so far proven elusive. Although in recent years the introduction of 
broadly based chemotherapeutic interventions such as all-trans retinoic acid, cytosine 
arabinoside, histone deacetylase and DNA methyltransferase inhibitors has increased the 
survival rates in some leukemia patients (Altucci et al., 2005; Downing, 2008; Liedtke and 
Cleary, 2009), molecular therapies that target MLL1 are still lacking. Recent advances in 
our understanding of the protein-protein interactions involving MLL1 suggest several 
novel therapeutic strategies for targeted inhibition of MLL1 or MLL1 chimeric fusion 
activity in leukemic cells. These advances are reviewed in sections 3-6 (and are 
summarized in Figure 8).  
4. Targeting MLL1-Menin interaction as a therapeutic strategy to treat Mixed 
Lineage Leukemia 
4.1 Menin is a common component of wild-type and mutant MLL1 complexes 
Despite the growing evidence demonstrating a role for HOX genes in hematopoiesis, it is 
unclear how the array of mutations involving the MLL1 gene all contribute to altered HOX 
gene expression in acute leukemias. While there is little that is common among the different 
types of MLL1 aberrations, all types of MLL1 gene mutations including: chromosomal 
translocations, internal partial tandem duplications, and gene amplifications, retain the N-
terminus of MLL1 (Daser and Rabbitts, 2005; Hess, 2004; Mitterbauer-Hohendanner and 
Mannhalter, 2004). These ~1400 N-terminal amino acids contain the DNA binding AT-hooks 
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and CXXC domains as well as the binding site for nuclear proteins menin (called the Menin 
Binding Motif or MBM) and the LEDGF binding domain (LBD) (Figures 1 and 2). Menin, 
which directly binds wild-type MLL1 and MLL1-oncogenic fusion proteins, is an essential 
co-factor for the maintenance of normal hematopoiesis and the leukemogenic activity of 
MLL1-associated translocations (Chen et al., 2006b; Hughes et al., 2004; Yokoyama et al., 
2005; Yokoyama et al., 2004). The importance of menin in the pathogenesis of MLL1-related 
leukemia and progress on the development of inhibitors that target the MLL1-menin 
interaction is reviewed in this section.  
4.2 MEN1 tumorigenesis 
Menin is the product of MEN1 gene located at chromosome band 11q13.  Menin functions as 
a tumor suppressor protein that is mutated in patients with an inherited syndrome called 
Multiple Endocrine Neoplasia 1 (MEN1) (Chandrasekharappa et al., 1997; 
Chandrasekharappa and Teh, 2001; Larsson et al., 1988). To date, more than 400 nonsense 
and frame-shift mutations have been reported in MEN1 patients often developing 
parathyroid, pancreatic or pituitary tumors after the loss of the wild-type MEN1 allele 
(Dong et al., 1997; Larsson et al., 1988; Lemmens et al., 1997; Thakker, 2001). Homozygous 
knockout of MEN1 (-/-) is embryonic lethal in mice, which die at the mid-gestation period 
with profound defects in liver, heart and the neural tube (Bertolino et al., 2003a; Crabtree et 
al., 2001; Stewart et al., 1998). Heterozygous knockout mice are viable until the adult stages, 
but develop tumors similar to human MEN1 syndrome in pancreatic islets, parathyroid, 
anterior pituitary, adrenal cortex and adrenal medulla (Bertolino et al., 2003b; Crabtree et al., 
2001). Although the loss of menin results in tumors of the endocrine lineage, the MEN1 gene 
is ubiquitously expressed in most adult tissues and at all developmental stages 
(Chandrasekharappa and Teh, 2001, 2003). In spite of the increasing evidence that highlights 
a role for menin in MEN1 tumors, the basic biology of menin dependent tumor suppression 
is unclear.  
4.3 Menin homology and conserved domain architecture 
Menin is highly conserved among vertebrates including, humans, mouse, rat, and 
zebrafish. However, menin orthologs have not been identified in budding yeast 
Saccharomyces cerevisiae or in the nematode Caenorhabditis elegans (Stewart et al., 1998) 
(Guru et al., 1999; Guru et al., 2001; Khodaei et al., 1999; Manickam et al., 2000). Strikingly, 
several of the disease-associated MEN1 mutations occur at conserved amino acid 
positions, highlighting a crucial role for menin in regulating cell proliferation in higher 
eukaryotes (Chandrasekharappa and Teh, 2003; Poisson et al., 2003). Menin is a novel 
nuclear protein of ~610 amino acids and does not share significant sequence homology to 
any other known proteins (Chandrasekharappa et al., 1997; Guru et al., 1998; Poisson et 
al., 2003). However, extensive analysis of sequence alignments among menin homologues 
has revealed several domains with putative roles in nuclear targeting and transcriptional 
regulation. Conserved domain search using the human menin amino acid sequence 
identified putative domains such as: consensus GTPase-like motifs (G1-G5), two leucine-
zipper motifs, a proline-rich region and two nuclear localization signals (NLS) (Balogh et 
al., 2006; Chandrasekharappa and Teh, 2003; Poisson et al., 2003) (Figure 3). However, it is 
unclear as to how these conserved motifs contribute to the tumor suppressor function of 
menin.  
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Schematic representation of the conserved regions in human menin with the various functional 
domains indicated in different colors:  GTPase consensus-motifs G1-G5 (black), leucine-zipper-like 
motifs (purple), proline-rich sequence (blue), and nuclear localization signal (NLS) (orange). Naturally 
occurring MEN1 mutations that disrupt its interaction with MLL1 (green) and LEDGF (red) are 
indicated below.  
Fig. 3. Domain architecture of human menin showing conserved domains  
4.4 Menin molecular interaction network 
The precise biochemical function of menin has so far proven elusive due to the lack of any 
known functional domains in menin. However,  it has been suggested that the 
transcriptional regulatory properties of menin are regulated by protein-protein 
interactions (Balogh et al., 2006; Jin et al.; Poisson et al., 2003; Yokoyama and Cleary, 2008; 
Yokoyama et al., 2004). Recent biochemical efforts have been undertaken to elucidate the 
molecular pathways that underlie menin-dependent transcriptional regulation (Balogh et 
al., 2006). Using yeast two-hybrid, GST pull-down and co-immunoprecipitation assays, 
menin was shown to interact with a cohort of proteins that are involved in cell cycle 
regulation, DNA replication and repair, genome stability, endocrine metabolism, bone 
morphogenesis and hematopoiesis (Balogh et al., 2006; Chandrasekharappa and Teh, 
2003; Hughes et al., 2004; Wu and Hua, 2008). These studies uncovered a wide variety of 
proteins that may or may not interact directly with menin. These proteins (menin 
interacting proteins or MIPs) can be grouped into four major functional classes: Class I, 
which includes transcription factors like JunD (Agarwal et al., 1999; Gobl et al., 1999; 
Heppner et al., 2001), NFkB (p50, p52 and p65) (Heppner et al., 2001), Smad3 (Kaji et al., 
2001), BMP2 (bone morphogenic protein 2) (Sowa et al., 2004), IGFBP-2 (Insulin-like 
growth factor binding protein 2) (La et al., 2004), FANCD2 (fanconi anemia 
complementation group D2 protein) (Jin et al., 2003), Pem (a homeobox containing 
transcription factor) (Lemmens et al., 2001), cMyb (Jin et al.); Class II, which includes 
DNA damage and replication proteins such as RPA (replication protein A 1 and 2) 
(Sukhodolets et al., 2003); Class III, which includes cell cycle regulatory proteins such as 
CDK inhibitors (p18 and p27) (Milne et al., 2005),  ASK (activator s-phase kinase) 
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(Schnepp et al., 2004), type III intermediate filaments (glial fibrillary acidic protein or 
GFAP and Vimentin) (Lopez-Egido et al., 2002); and Class IV, which includes 
transcriptional activators such as MLL1/2 (mixed lineage leukemia proteins) (Hughes et 
al., 2004; Yokoyama et al., 2004), RNA polymerase II phosphorylated carboxy terminal 
domain (Hughes et al., 2004), LEDGF (Yokoyama and Cleary, 2008), and CHD1 (chromo 
domain helicase I) (Chen et al., 2006b). Based on these studies it has been suggested that 
MIPs modulate the transcriptional activator/repressor functions of menin (Agarwal et al., 
1999; Agarwal et al., 2003; Heppner et al., 2001; Kaji et al., 2001). While a direct role for the 
interaction of menin with all MIPs has yet to be validated in vivo, it is possible that MIPs 
regulate transcription by binding directly or indirectly to menin (Balogh et al., 2006; 
Chandrasekharappa and Teh, 2003; Wu and Hua, 2008). In addition, menin also binds to a 
putative tumor metastasis suppressor/nucleoside diphosphate kinase (Nm23), which 
stimulates the GTP hydrolyzing activity of menin (Ohkura et al., 2001). Moreover, menin 
also functions as a transcriptional co-activator of the nuclear receptor pathway by binding 
with estrogen receptor-alpha (ERalpha) in a hormone-dependent manner (Dreijerink et 
al., 2006). A non-specific DNA binding activity through the C-terminal NLS has also been 
reported for menin (La et al., 2004). Of the multitude of interactions reported for menin, it 
is the association with the SET1 family methyltransferases MLL1/2 that has generated a 
lot of interest due to their roles in hematopoiesis and leukemia.  
4.5 Role of menin in Hematopoiesis 
Menin is an essential component of MLL1/2 family complexes with specific roles in the 
maintenance of HOX gene expression patterns during hematopoiesis (Hughes et al., 2004; 
Yokoyama et al., 2004).  Conditional knockouts of the MEN1 gene in mice decreases 
peripheral white blood cell counts as well as colony forming potential of bone marrow 
hematopoietic progenitors (Chen et al., 2006b). Recent work by Maillard et al., (2009a), 
suggests that while conditional menin knockouts have modest effects on hematopoiesis 
under steady-state conditions, more severe defects are observed in competitive 
transplantation assays and during drug-mediated chemoablation (Maillard et al., 2009). 
These studies suggest that menin functions as an essential regulator of hematopoietic stem 
cell (HSC) homeostasis specifically in situations of hematopoietic stress (Maillard and Hess, 
2009). These phenotypes may be due, at least in part, to menin’s role in regulating HOX gene 
expression. For example, small-interfering RNA (siRNA) mediated knockdown of menin or 
conditional MEN1 (-/-) knockout embryos show significant decreases in the expression 
levels of several HOX genes including HOXa9, HOXc6, and HOXc8 (Chen et al., 2006b; 
Hughes et al., 2004; Wu and Hua, 2008; Yokoyama et al., 2004). Interestingly, these 
hematopoietic defects are rescued by the ectopic expression of menin or its downstream 
targets HOXa9/MEIS1 (Chen et al., 2006b; Hughes et al., 2004). Evidence indicates that 
menin’s interaction with MLL1/2 complexes is required for its role in transcription. For 
example, chromatin immunoprecipitation studies using antibodies specific to menin, MLL1, 
trimethylated H3K4 or CHD1 (which binds trimethylated H3K4) (Flanagan et al., 2005; 
Pray-Grant et al., 2005; Sims et al., 2005) have further established that menin co-localizes 
with these components at HOXa9 promoters and is required for transcriptional activation 
(Chen et al., 2006b; Wu and Hua, 2008). Furthermore, it has been shown that a subset of 
naturally occurring mutations in menin (H139D, A242V, and T344R) disrupts its association 
with MLL1 and fails to associate with MLL1-dependent H3K4 methyltransferase activity 
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(Hughes et al., 2004) (Refer to figure 3 for MEN1 mutations). These findings underscore the 
importance of the menin-MLL1 interaction in regulating HOX gene expression in 
hematopoiesis.  
4.6 Role of menin in leukemogenesis 
The first evidence for the involvement of menin in MLL1-associated leukemogenesis came 
from the initial biochemical studies carried out by Yokoyama et al., (2005) who identified a 
menin binding motif (MBM) located within the first 330 amino acids of MLL1, a region that 
is also retained in all types of MLL1 aberrations (Figures 1 and 2) (Yokoyama et al., 2005). 
Using leukemia cells that carry specific MLL1-translocations (MLL1-AF6, MLL1-ENL, 
MLL1-AF9, MLL1-AF10, and MLL1-GAS7) it was demonstrated that menin specifically 
associates with these MLL1-fusion proteins at the promoter of HOX genes such as: HOXa7, 
HOXa9 and HOXa10, which are constitutively expressed in several cases of acute leukemia 
(Chen et al., 2006b; Yokoyama et al., 2005; Yokoyama et al., 2004). Acute loss of menin 
reduces the aberrant HOX gene expression and abrogates the differentiation arrest 
associated with these MLL1-fusions (Yokoyama et al., 2005). Furthermore, conditional 
knockouts of the MEN1 gene suggests that menin is essential for the initiation and 
maintenance of MLL1-associated, but not other oncogene induced, myeloid transformations 
(Caslini et al., 2007; Chen et al., 2006b; Yokoyama et al., 2005). Together, these results 
demonstrate that MLL1-fusion proteins are dependent on menin for their oncogenic 
properties and raise the possibility that molecular therapies that target the menin-MLL1 
interaction might be an effective strategy to treat leukemias.  
While it is unclear how menin modulates the activities of wild-type and MLL1-fusion 
proteins, recent studies suggest that menin functions to recruit other proteins that are 
required for targeting MLL1 to downstream genes. For example, a recent study by 
Yokoyama and Cleary (2008) suggests that menin promotes LEDGF binding to MLL1. 
LEDGF contains a highly conserved PWWP motif that is required for MLL1’s association 
with downstream target genes (Yokoyama and Cleary, 2008). In addition, menin amino acid 
substitutions that disrupt its interaction with LEDGF without affecting menin’s interaction 
with MLL1 also display decreased Hoxa9 gene expression (Roudaia and Speck, 2008; 
Yokoyama and Cleary, 2008).  These data indicate that part of menin’s function is to stabilize 
the interaction between MLL1 and LEDGF. More recently, it has been shown that menin 
recruits the transcription factor cMyb to the MLL1 complex, which is required for 
recruitment of MLL1 to the Hoxa9 promoter (Jin et al., 2010). It has been shown that 
depletion of cMyb decreases the transforming potential of the MLL1-ENL fusion protein (Jin 
et al., 2010), suggesting that molecules that inhibit the menin-cMyb interaction may also be 
useful therapeutic agents.  
4.7 Menin interacts with the N-terminus of MLL1 through an evolutionarily conserved 
Menin Binding Motif (MBM)  
The interaction of menin with N-terminal sequences of wild-type MLL1 and MLL1-chimeric 
fusion proteins have been demonstrated by three independent reports (Caslini et al., 2007; 
Grembecka et al., 2010; Yokoyama et al., 2005). While the conclusions of these studies differ 
with respect to the exact length of the MLL1 fragment predicted to be involved in the 
interaction with menin, they have collectively identified a highly conserved “menin binding 
motif” (MBM) localized within the first 46 residues of MLL1. For example, Yokoyama et al., 
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(2005) demonstrated that a consensus sequence (RXRFP), called the high-affinity MBM, is 
present between MLL1 amino acids 6-10. Sequence analysis reveals that the MBM is highly 
conserved among MLL1 orthologs and in MLL2 (residues 17-21) (Figure 3). Deletions of the 
MBM in the MLL1-ENL and MLL1-GAS7 fusion proteins abrogates the interaction with 
menin in 293T cells (Yokoyama et al., 2005). Furthermore, MLL1-ENL fusions that lack the 
MBM fails to induce acute myeloid leukemia in syngeneic recipient mice (Yokoyama et al., 
2005). This failure is associated with impaired expression of HOXa7 and HOXa9 genes in the 
MBM-deleted MLL1-ENL transduced murine myeloid progenitors (Yokoyama et al., 2005). 
Moreover, MBM deletion mutants of MLL1-ENL lose their clonogenic potential and induce 
differentiation in leukemia blasts, a phenotype similar to the conditional knock out of menin 
or MLL1-ENL itself (Ayton and Cleary, 2003; Yokoyama et al., 2005; Zeisig et al., 2004). 
These studies demonstrate the importance of menin-MLL1 interaction in the pathogenesis of 
MLL1-associated leukemias.  
 
 
The different functional domains in MLL1 are indicated and color coded as in Figure 1. The menin 
binding motif  encompassing residues 5-44 (purple) along with LEDGF binding domain (LBD)(light 
red), AT-hooks (black), and the CXXC motif (pink) are retained by both MLL1-translocations and PTD 
mutations. The blow up region shows a ClustalW multiple sequence alignment of the high affinity 
menin binding motifs, MBM1 and MBM2, present in human (Q03164), mouse (NP_001074518), 
zebrafish (ACN88688), and pufferfish (AAC41377) MLL1s; and human MLL2 (O14686), and MLL1-AF4 
(AAC37520) fusions (indicated in purple). MBM1 and 2 were identified based on three independent 
studies (Yokoyama et al., 2005; Caslini et al., 2007; Grembecka et al., 2010).  
Fig. 4. Menin Binding Motifs (MBMs) are present in the wild-type MLL1, MLL1 chimeric 
fusions and partial tandem duplications  
In an attempt to further characterize the physiological significance of the MLL1-menin 
interaction in acute leukemias, Caslini et al., (Caslini et al., 2007) demonstrated that MLL1 
residues 5-44 are required for high affinity binding with menin. This MBM region spans the 
RWRFP motif (residues 6-10) and also includes a second region between MLL1 residues 35 
and 44 that is necessary, but not sufficient, for high-affinity interaction with menin (Caslini 
et al., 2007). Internal deletions in the MLL1-AF9 fusion protein that lacked amino acids 5-15 
(high affinity MBM) or 35-44 (low affinity MBM) failed to co-immunoprecipitate with menin 
from 293T cells (Caslini et al., 2007). Furthermore, Caslini et al., (2007) also demonstrated 
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that MLL1-AF9 MBM sequences were essential for the transformation of hematopoietic 
progenitors by the MLL1-AF9 fusion protein. Interestingly, the MLL1 constructs MLL1(2-
167), MLL1(2-62), and MLL1(2-44) function as dominant negative inhibitors of the MLL1-
menin interaction by titrating menin from the endogenous MLL1-AF9 protein resulting in 
reduced HOXa9 and MEIS1 expression and inhibition of the growth of transformed bone 
marrow progenitors (Caslini et al., 2007). Together, these results suggest that expression of 
dominant negative MLL1 constructs or peptide inhibitors that mimic the MLL1-menin 
interaction can inhibit the transforming potential of MLL1-fusion proteins by specifically 
down regulating the expression of target HOX genes. Unexpectedly, dominant negative 
constructs of MLL1 also inhibited the colony-forming ability of wild-type hematopoietic 
progenitors since these constructs also mimic the interaction surface between wild-type 
MLL1 and menin (Caslini et al., 2007). Collectively, these findings suggest that small 
molecule inhibitors that target menin-MLL1 interaction have a therapeutic potential to treat 
MLL1-associated leukemias, but with the caveat that normal hematopoiesis might also be 
impaired (Caslini et al., 2007). 
4.8 MBM based peptides as novel therapeutic agents for acute leukemias with MLL1-
rearrangements 
Structural and biochemical studies that characterize the menin-MLL1 interaction in detail is 
an important step in the development of MBM-based small molecule inhibitors that can 
specifically help treat MLL1-mediated cancers. Grembecka et al., (2010) carried out a 
detailed biophysical characterization of the interaction between menin and MLL1 using a 
combination of NMR, Isothermal Titration Calorimetry (ITC) and Fluorescence Anisotropy 
(FP). They found that MLL1 binds menin with high affinity (Kd=~10nM) utilizing two 
menin binding motifs (MBM1 and 2) located within the first 43 amino acids of MLL1 as 
previously suggested (Caslini et al., 2007; Yokoyama et al., 2005). Furthermore, peptides 
derived from the MBM1 (amino acids 5-14) and MBM2 (23-40) in MLL1 bind menin with 
interaction affinities of 53nM and 1400nM, respectively (Grembecka et al., 2010). Using a 
series of peptide competition experiments, MBM1 and MBM2 peptides were shown to 
displace a construct of MLL1 (amino acids 2-43) from bound menin in vitro with IC50 values 
of 0.5 µM and 37 µM, respectively (Grembecka et al., 2010). Moreover, based on transfer-
nuclear overhauser effects (Tr-NOEs) based NMR experiments, it was further suggested that 
MBM1 interacts with menin in an extended conformation and that the binding is facilitated 
by hydrophobic residues Phe9, Pro10 and Pro13 (Grembecka et al., 2010). Substitution to 
alanine of these amino acid residues significantly impaired the binding of MLL1 constructs 
to menin (Grembecka et al., 2010). Together, these studies have identified MBM1 (which 
encompasses the consensus RWRFP) as a potential drug target for leukemias with MLL1 
translocations.   
5. Molecular targeting of MLL1-rearranged leukemias - Peptide inhibitors that 
target the activity of MLL1-AF4 and MLL1-AF9 fusion proteins 
5.1 Clinical significance of t(4;11) and t(9;11) translocations 
MLL1 translocations do not share a common structural motif or biochemical function.  
However, based on sequence similarities, the most commonly occurring MLL1 fusions can 
be grouped into three major gene families: AF10/AF17, ENL/AF9, and the largest family, 
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AF4/LAF4/AF5q31/FMR2 (Nilson et al., 1997). The most common translocation is 
t(4;11)(q21;q23) and is associated with more than 50% of acute leukemia cases in infants, and 
for 3-6% of cases in older children (Behm et al., 1996; Faderl et al., 1998; Heerema et al., 
1999). The t(4;11) translocations results in leukemic blasts expressing phenotypic markers for 
ALL in 95% of the cases (Chen et al., 1993; Pui et al., 2003)). t4:11 translocations result in 
cancers that often spread beyond the hematopoietic lineage and have a poor prognosis 
(Armstrong et al., 2002; Chen et al., 1993; Rubnitz et al., 1994a). The t(4:11) translocation 
retains the 5’ portion of MLL1 gene containing the menin binding motif (MBM), AT hooks 
and the CXXC DNA binding motifs, which are fused in-frame to the 3’ portion of the gene at 
the 4q21 locus called AF4 (Gu et al., 1992). The high occurrence rates of t(4;11) translocation 
in infants along with the poor prognosis and absence of chemotherapeutics to treat these 
leukemias highlight an urgent need for the development of inhibitors that specifically target 
the gain-of-function phenotypes associated with the MLL1-AF4 fusion. In this regard, 
inhibitors that target the interaction between AF4 and its partner protein AF9 have been 
developed recently and show promising results in inhibiting the transforming potential of 
leukemia cell lines bearing MLL1-AF4 or MLL1-AF9 translocations (Bennett et al., 2009; 
Palermo et al., 2008; Srinivasan et al., 2004). The biochemical studies that form the basis for 
these conclusions are summarized in this section.  
5.2 Domain architecture and the functional roles of AF4 family 
AF4, also known as AFF1/FEL, is a serine/proline-rich nuclear protein with crucial roles in 
B and T lymphocyte development. AF4 has several putative functional domains including 
the ALF (AF4/LAF4/FMR2 homology) domain, which  mediates the interaction with a 
family of ubiquitin ligases called SIAH (seven in absentia homolog), a serine/proline-rich 
transcriptional activation domain (TAD), nuclear localization signals (NLS), a guanosine 
triphosphate (GTP) binding motif (GBM), and  a C-terminal homology domain involved in 
intra-nuclear localization and binding to pre-mRNA splicing factors (Bensaid et al., 2009; 
Chen et al., 1993; Isnard et al., 2000; Melko et al.; Morrissey et al., 1993; Oliver et al., 2004) 
(Figure 5). AF4 is located at a fragile break-point region on chromosome 4 and is associated 
with a wide variety of chromosomal translocations. AF4 is a member of 
AF4/LAF4/AF5q31/FMR2 family of nuclear transcription factors (Gu et al., 1996; von 
Bergh et al., 2001; von Bergh et al., 2002) and also shows significant homology to the 
Drosophila melanogaster pair-rule gene Lilliputian  (Su et al., 2001). Surprisingly, three of 
these family members (AF4/LAF4/AF5q31) are associated with infant leukemias involving 
reciprocal translocations with the MLL1 gene (Domer et al., 1993; Ma and Staudt, 1996; Taki 
et al., 1999). The second family member LAF4, isolated from Burkitt’s lymphoma, is a 
lymphoid-specific transcription factor and has transcriptional activation domains and 
nuclear localization signals that are highly similar to AF4 (Ma and Staudt, 1996). Indeed, the 
MLL1-LAF4 fusion proteins also retain the TAD in LAF4, which can functionally substitute 
for the activation domain in MLL1, thereby the contributing to the leukemogenic potential 
of these chimeric fusion proteins (Ma and Staudt, 1996). The third AF4 homologue AF5q31 
was originally identified from infant acute leukemias with a (5;11)(q31;q13q23) translocation 
(Taki et al., 1999). Strikingly, each of these MLL1-AF4 gene family fusions manifest very 
similar clinical characteristics- that is, early onset, poor prognosis, and a mixed 
immunophenotype. However, the fourth AF4 family member, FMR2, is associated with 
mental retardation and is located in the folate-sensitive break-point region at chromosome X 
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band q28 (Gecz, Gedeon et al. 1996; Gu, Shen et al. 1996). FMR2 has not been reported to be 
a part of any MLL1 fusions.  
 
 
Overview of the protein domain structure of human AF4 adapted from (Li et al., 1998; Srinivasan et al., 
2004 and Melko et al., 2011). The different domains are highlighted: N-homology region with an 
unknown function (green), ALF (AF4/LAF4/FMR2 homology) region which includes the transcription 
activation domain (dark red), AF9 interaction region (orange), nuclear localization signals (dark blue), a 
putative consensus guanosine triphosphate (GTP) binding motif (purple), and C-terminal homology 
domain (light blue). The domains are not drawn to scale. The ClustalW multiple protein sequence 
alignment of the AF9 binding regions of AF4 family members: human AF4 (hAF4, Pubmed ID: P51825), 
mouse AF4 (mAF4, Pubmed: AAU93698), human LAF4 (hLAF4, PubMed ID: NP002276), human AF5 
(hAF5, PubMed ID: Q9UHB7), human FMR2 (hFMR2, PubMed ID: BAC81113) and mouse FMR2 
(mFMR2, PubMed ID: CAA04821) are shown with the AF9 interaction region boxed. Chromosomal 
break points are also indicated for cell lines carrying t(4;11) translocations. 
Fig. 5. Domain representation of human AF4 highlighting the AF9 interaction region. 
Despite the growing amount of clinical evidence suggesting the involvement of MLL1-AF4 
family translocations in human acute leukemias, the molecular mechanisms by which the 
MLL1-AF4 fusion proteins induce neoplasia are not fully understood. One possibility is that 
the resulting MLL1-AF4 fusion protein has a gain-of function phenotype wherein the 
transcriptional activation domain of AF4 is fused to the DNA binding domains of MLL1 and 
alters the regulation of MLL1 dependent genes  (Prasad et al., 1995). However, genetic 
studies using mouse knock-in models suggest that the two fusion proteins MLL1-AF4 and 
AF4-MLL1 resulting from the balanced reciprocal translocation between MLL1 and AF4 
could independently contribute to the pathogenesis of t(4;11) mediated acute leukemias 
(Bursen et al.; Chen et al., 2006a; Isnard et al., 2000). Importantly, the AF4-MLL1 fusion 
protein retains the C-terminal portion of MLL1 including its SET domain, and is sufficient to 
induce leukemia in the absence of MLL1-AF4 (Bursen et al., 2010).  
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5.3 Molecular interaction network for AF4 fusion proteins 
These studies raise the possibility that MLL1-AF4 and AF4-MLL1 participate in different 
sets of interaction networks as compared to the native full-length proteins (MLL1 and AF4) 
and result in gene expression signatures that are a representative of the physiological 
function of the fusion partners. This hypothesis is supported by the studies of Benedikt et 
al., (2011), who used affinity purified AF4 and AF4-MLL1 complexes from 293T cells to 
elucidate the subunit composition of the two complexes (Benedikt et al., 2011). Wild-type 
AF4 was purified in a complex containing the CDK9/Cyclin T heterodimer, which 
resembles the positive transcription elongation factor b (p-TEFb) (Benedikt et al., 2011; 
Estable et al., 2002) and also co-purifies with the wild type versions of two other known 
MLL1 fusion partners, AF9 and ENL, both of which bind to the C-terminus of AF4 family 
members (Benedikt et al., 2011; Erfurth et al., 2004; Mueller et al., 2009). Furthermore, ENL 
binding to AF4 creates a binding site for AF10, DOT1 methyltransferase and histone H3 
(Benedikt et al., 2011; Mueller et al., 2007). Both the DOT1 mediated H3K79 methylation and 
the p-TEFb mediated phosphorylation of RNA Pol II C-terminal domain could lead to 
transcriptional elongation and is facilitated by the interaction of wild-type AF4 with these 
proteins (Benedikt et al., 2011; Bitoun et al., 2007). In contrast, the subunit composition of the 
AF4-MLL1 complex is different from the wild-type AF4 protein alone due to additional 
proteins that interact with the fused MLL1 C-terminal fragment. These proteins likely 
modulate the transcriptional activating properties of AF4-MLL1 fusion protein (Benedikt et 
al., 2011). MLL1-AF4 chimeric fusions on the other hand have an intact C-terminus of AF4 
and therefore retain the transcriptional activation domains and its ability to interact with 
AF9 and ENL. 
5.4 Functional significance of AF9/ENL family 
Reciprocal translocations involving the AF9 (t(9;11)(p22;q23)) and ENL (t(11;19)(q23;p13)) 
genes are also associated with several cases of ALL and AML (Mitelman and Heim, 1992). 
Similar to AF4, AF9 also belongs to a family of serine/proline-rich transcription factors 
(Hemenway et al., 2001; Nakamura et al., 1993; Prasad et al., 1995) and shares significant 
similarity to ENL and the yeast protein ANC1 (Rubnitz et al., 1994b; Welch and Drubin, 
1994). Interestingly, ANC1 has been demonstrated to be a part of the yeast RNA polymerase 
II complex, as well as the SWI/SNF nucleosome-remodeling complex, a macromolecular 
complex which functions as ATP-dependent chromatin remodeler (Cairns et al., 1996; 
Carlson and Laurent, 1994; Cote et al., 1994). The high degree of sequence similarity 
between human AF9/ENL and the yeast ANC1 protein has led to the hypothesis that AF9 
and ENL may also interact with a human SWI/SNF remodeling complex similar to yeast 
ANC1, and the MLL1-AF9/ENL fusion proteins may retain these features.  The biological 
functions of AF4, AF9 and ENL are not clearly understood, however, gene deletion studies 
in mice have demonstrated important roles for these proteins during development (Collins 
et al., 2002; Doty et al., 2002; Isnard et al., 2000). Furthermore, the endogenous ENL protein 
was purified as a part of a macromolecular complex (ENL associated protein complex or 
EAP) that also contains p-TEFb, DOT1 and AF4 and plays a putative role in transcriptional 
elongation (Bitoun et al., 2007; Mueller et al., 2007). Despite the fact that MLL1-AF4 
translocations and MLL1-AF9/ENL fusions account for more than 50% of MLL1 11q23 
associated leukemias (Burmeister et al., 2009; Meyer et al., 2009; Meyer et al., 2006), there 
exists no functional similarity between these MLL1 fusion partners. It is tempting to 
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hypothesize that MLL1 fusion proteins might hijack the p-TEFb/DOT1 mediated 
transcriptional elongation activity or the SWI/SNF dependent nucleosome remodeling 
activity through the fusion partner and result in constitutive target gene expression leading 
to leukemia. These studies suggest that pTEFb, DOT1 and the MLL1 fusion partners 
AF4/AF9/ENL are all molecular targets in the development of therapeutics that target 
MLL1-fusion mediated leukemias.  
5.5 Domain mapping of the interaction region between AF4 and AF9 
Co-localization studies carried out by (Erfurth et al., 2004) have established that the two 
most common MLL1 fusion partners AF4 and AF9 form a stable complex within the nucleus 
and are restricted to discrete nuclear foci called “AF4 bodies”. AF4 bodies are nuclear 
speckle-like in appearance and are distinct from the nucleolus, cajal bodies, PML body or 
regions associated with DNA replication and repair (Erfurth et al., 2004). Using yeast two-
hybrid screens it was demonstrated that the minimum motif in human AF4 required for 
binding AF9 encompasses 14 residues (761-774) that are proximal to the bipartite nuclear 
localization signal (NLS) in AF4 (refer to figure 5 for domain representation). Deletion of 
these residues completely abolishes the interaction between AF4 and AF9 and also results in 
diffuse AF4 bodies (Erfurth et al., 2004; Srinivasan et al., 2004). Site-directed mutagenesis 
studies reveals that bulky hydrophobic residues within the conserved AF9 binding region in 
mouse AF4 ( mAF4 ) dictate its binding affinity to AF9 (Srinivasan et al., 2004). Using 
fluorescent tagged AF4 and AF9 constructs it was further demonstrated that both the 14 
residue AF9 binding motif and the bipartite NLS was required for the punctate nuclear 
speckle distribution of AF4-AF9 complexes (Erfurth et al., 2004).  Likewise, the terminal 93 
residues in AF9 (and the terminal 84 in the case of ENL) were identified as the minimal 
region required for binding AF4 (Erfurth et al., 2004). Interestingly, the mutual interaction 
domains between AF4 and AF9 are highly conserved in the AF4 and AF9 homologues (refer 
to figure 5 for sequence alignment) (Erfurth et al., 2004; Srinivasan et al., 2004) and the AF4-
AF9 interaction region is retained by the MLL1 fusion proteins (MLL1-AF4 and MLL1-AF9) 
(Dobson et al., 1999; Domer et al., 1993; Erfurth et al., 2004), suggesting that AF4-AF9 
interaction might be an important step in the pathogenesis associated with these MLL1 
fusions. The functional significance of the interaction between AF4 and AF9 is unclear; 
however, the co-localization of these two proteins to specific sub-nuclear foci suggests that 
AF4-AF9 interaction might be required for normal cellular functions as well as in the 
pathogenesis of MLL1-AF4 or MLL1-AF9 associated leukemias (Erfurth et al., 2004). 
Furthermore, the presence of this interaction region in MLL1-AF4 and MLL1-AF9 fusion 
proteins, and the ability of MLL1-AF4 fusions to alter the localization of endogenous AF9 
also suggest that AF4-AF9 protein complex is a pharmacological target for leukemia therapy 
(Erfurth et al., 2004; Srinivasan et al., 2004).  
5.6 A synthetic peptide PFWT disrupts the interaction between AF4 and AF9  
Based on the initial mapping studies of the AF9 binding region in AF4, a synthetic peptide, 
designated “PFWT” that mimics the interaction region was developed and tested for its 
ability to disrupt the AF4-AF9 interaction both in vitro and in vivo (Erfurth et al., 2004; 
Srinivasan et al., 2004). The initial PFWT peptide developed in this study was based on the 
highly conserved AF4-AF9 interaction sequence in the mouse FMR2 protein and 
encompasses residues (759-771) (see Figure 5 for the sequence alignment of the AF9 
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interaction region in AF4 family members). To enable nuclear uptake, the PFWT peptide 
was conjugated to a penetratin transporter sequence at its N-terminus (Srinivasan et al., 
2004). Using pull-down assays with GST-tagged AF4 and biotinylated AF9, it was shown 
that this PFWT peptide disrupts the interaction between human AF4 and AF9 in a 
concentration dependent manner (Srinivasan et al., 2004). However, a control peptide 
(containing amino acid substitutions at V763E and I765S) did not interfere with the binding 
of AF4-AF9 complex (Srinivasan et al., 2004). The specificity of PFWT peptide against AF4-
AF9 complexes was further demonstrated by its inability to disrupt the interaction between 
AF9 and two other proteins, the Polycomb protein (MPC3) and the mouse homolog of BCL-
6 co-repressor (mBCoR), both of which interact through the C-terminus of AF9 (Hemenway 
et al., 2001; Srinivasan et al., 2003; Srinivasan et al., 2004). Furthermore, the PFWT peptide 
was shown to be readily taken up by NIH3T3 cells and disrupts the co-localization of AF4-
AF9 in vivo (Srinivasan et al., 2004). These results corroborated the in vitro findings that the 
PFWT peptide has the ability to specifically disrupt the interaction between AF4 and AF9 
protein complexes.  
5.7 PFWT peptide inhibits the cell proliferation of leukemia cell lines with t(4;11) and 
t(9;11) translocations 
Based on these observations it was further predicted that the PFWT peptide will have the 
ability to inhibit the proliferation of leukemia cell lines that carry a t(4;11)(q21;q23) or 
t(9;11)(p22;q23) translocations (Bennett et al., 2009; Palermo et al., 2008; Srinivasan et al., 
2004). As expected, PFWT peptide specifically inhibits the proliferation of leukemia cell lines 
B1, MV4-11 and RS4;11 (Cohen et al., 1991; Lange et al., 1987; Stong et al., 1985) that harbor 
the MLL1-AF4 translocation (Bennett et al., 2009; Palermo et al., 2008; Srinivasan et al., 2004). 
Interestingly, the PFWT peptide also inhibits the survival capacity of KP-L-RY cell lines 
(Cohen et al., 1991) that are characterized by a t(5;11) translocation associated with MLL1-
AF5q31 fusions (Srinivasan et al., 2004). In contrast to cell lines that carry either the MLL1-
AF4 or MLL1-AF5q31 translocations, the PFWT peptide shows mixed effects in the 
inhibition of the proliferative capacity of leukemia cell lines that carry MLL1-AF9 
translocations (Palermo et al., 2008; Srinivasan et al., 2004).). For instance, based on the study 
by (Srinivasan et al., 2004), the PFWT peptide failed to inhibit the growth of THP-1 cells 
(Tsuchiya et al., 1980) that are associated with MLL1-AF9 translocations. However, a more 
recent study demonstrated that Molm13 leukemia cells that are also associated with MLL1-
AF9 translocations are sensitive to treatments with PFWT peptide in a dose dependent 
manner (Palermo et al., 2008). While these findings suggest that there are differences in the 
inhibitory properties of the PFWT peptide towards cell lines that carry a similar 
translocation, it highlights the fact that these leukemias might operate through additional 
pathways that lead to misregulated gene expression profiles (Palermo et al., 2008; Srinivasan 
et al., 2004). Furthermore, the specificity of PFWT peptide in inhibiting leukemia cells with 
MLL1-AF4 and MLL1-AF9 mutations is corroborated by the findings that the MOLT-4 (T-
ALL) cell line (Minowada et al., 1972) that does not contain a MLL1-AF4 translocation is not 
affected by the PFWT peptide even at higher doses (Srinivasan et al., 2004). However, the 
Reh (B-precursor) cell lines (Koziner et al., 1985) that do not carry a MLL1-AF4 chimeric 
fusion are susceptible to the PFWT peptide (Srinivasan et al., 2004). These results suggest 
that some cell lines might require the function of normal AF4-AF9 complexes for its 
carcinogenesis and these native complexes are also targeted by the PFWT peptides 
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(Srinivasan et al., 2004). Nevertheless, these findings demonstrate the wide range of 
specificity for the PFWT peptide and suggest that PFWT-like peptides are promising lead 
compounds in the development of treatment regimens for the most frequent 11q23 
translocations. The pharmacological importance of PFWT based peptides is further 
enhanced by the fact that these peptides have little effect on the number and colony forming 
potential of hematopoietic progenitor cells (Srinivasan et al., 2004), suggesting that PFWT-
like peptides may have fewer side effects .  
5.8 PFWT peptide as a lead compound in the treatment of MLL1-rearranged leukemias 
While initial studies suggest that the growth inhibitory properties of the PFWT peptide is 
mediated through apoptosis (Srinivasan et al., 2004), recent work by (Palermo et al., 2008) 
demonstrates that PFWT peptide induces cell death by necrosis in MV4-11 and Molm13 cell 
lines. Necrotic cell death was further demonstrated by the changes in plasma membrane 
integrity in the absence of traditional apoptotic markers: nuclear disintegration, caspase 
activation, DNA fragmentation or mitochondrial membrane depolarization (Palermo et al., 
2008). Given the resistance of t(4;11) translocations to conventional pro-apoptotic 
chemotherapeutic drugs, PFWT mediated necrotic cell death is an attractive alternative 
strategy to treat these acute leukemias. More recently, Bennett et al., (Bennett et al., 2009) 
demonstrated that the PFWT peptide in combination with standard chemotherapeutic 
agents such as etoposide, 17AAG (17-(allylamino)-17-demthoxygeldamycin), cytarabine, 
and Flt-3 kinase inhibitor results in synergistic cytotoxicity in MV4-11 cells that harbor 
t(4;11) translocations.  Furthermore, cell death was mediated through both apoptotic and 
necrotic pathways suggesting that PFWT peptides could be useful in combinatorial therapy 
to treat leukemia cell lines that are relatively resistant to current apoptotic drugs (Bennett et 
al., 2009; Campo Dell'Orto et al., 2007; Nakanishi et al., 2007; Wiederschain et al., 2005). 
Together, these findings emphasize that PFWT peptides inhibit the proliferation of t(4;11), 
t(5;11) and t(9;11) leukemia cell lines by specifically disrupting the association of AF4 or 
AF5q31 with AF9 and serves as a starting point for the development of more effective 
therapeutic strategies. In the absence of a crystal structure that clearly demonstrates the 
interaction mode between AF4 and AF9 proteins, systematic site-directed mutagenesis 
experiments can help identify amino acid positions that are more important for the overall 
binding affinity. Such an approach has the potential to help identify additional PFWT-based 
peptido-mimetic compounds that have better inhibitory properties than the initial PFWT 
peptide and prevent the potential toxic side effects that could occur at high doses of the 
PFWT peptide.  
6. Win motif-based inhibitors that target the assembly and enzymatic activity 
of the MLL1 core complex 
6.1 Novel strategies that target the histone methyltransferase activity of MLL1 
amplifications and MLL1-PTDs 
Growing evidence suggests that increased HOXa gene expression associated with MLL1 
amplifications and MLL1-PTDs underlie the pathogenesis of these leukemias (Basecke et al., 
2006; Dorrance et al., 2006). HOXa gene expression is dependent on the histone 
methyltransferase activity of MLL1 ((Milne et al., 2002), and given the increased H3K4 
methylation observed in MLL1-PTDs (Dorrance et al., 2008; Dorrance et al., 2006), inhibitors 
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that down-regulate the histone methyltransferase activity of MLL1-PTD have the potential 
to reverse this aberrant epigenetic program. Until recently, inhibitors that specifically target 
MLL1’s H3K4 methyltransferase activity have been difficult to develop due to lack of a clear 
understanding of MLL1’s structure and function. However, recent findings have established 
that H3K4 methylation levels are precisely regulated by the function of two independent 
methyltransferases: the MLL1 SET domain and a novel multi-subunit enzyme, WDR5-
RbBP5-Ash2L-DPY30 (WRAD), that lacks sequence homology to known methyltransferases 
(Patel et al., 2009; Patel et al., 2011). Because multiple methylation on H3K4 is catalyzed by 
two different enzymes, it is interesting to speculate that inhibitors that prevent the 
association of two methyltransferases will have clinical significance in the treatment of acute 
leukemias that are characterized by aberrant H3K4 methylation (Dorrance et al., 2008; 
Dorrance et al., 2006).  
6.2 WDR5 is central for the assembly and H3K4 methylation activity of MLL1 core 
complex 
The WD-40 repeat protein WDR5 is a conserved component of MLL1 family complexes 
ranging from yeast to humans and has been shown to be crucial for the assembly and H3K4 
dimethylation activity of MLL1 core complex HOX (Dou et al., 2006; Patel et al., 2008a; Patel 
et al., 2008b). Consistent with the role of WDR5 in the regulation of degree of H3K4 
methylation, siRNA mediated knock-down of WDR5 in mammalian cells results in a global 
decrease in the levels of H3K4 di- and trimethylation, down-regulation of HOXa9 and 
HOXc8 genes, and defects in hematopoiesis and development (Dou et al., 2006; Wysocka et 
al., 2005). WDR5 knock down and MLL1ΔSET mice show similar phenotypes suggesting 
that MLL1 and WDR5 function together to regulate H3K4 di/trimethylation and HOX gene 
expression in vivo (Terranova et al., 2006; Wysocka et al., 2005). Furthermore, growing 
evidence suggest that WDR5 interacts directly with MLL1 or other SET1 family members 
and functions as a scaffold to bridge the interactions between MLL1 and rest of the 
components of MLL1 core complex (Dou et al., 2006; Patel et al., 2008b; Trievel and 
Shilatifard, 2009; Wysocka et al., 2005). Indeed, MLL1 and WRAD enzymatic complexes fail 
to associate in the absence of WDR5 (Dou et al., 2006; Patel et al., 2008b), suggesting a crucial 
role for WDR5 in the assembly and H3K4 methylation activity of MLL1 core complex. 
6.3 WDR5 recognizes a conserved arginine containing sequence in the N-SET region 
of MLL1 
Previous studies have suggested that WDR5 functions within the MLL1 core complex as a 
histone “effector” or “presenter” domain, a domain that specifically recognizes methylated 
histones (Couture et al., 2006; Han et al., 2006; Ruthenburg et al., 2006; Schuetz et al., 2006; 
Trievel and Shilatifard, 2009; Wysocka et al., 2005). However, recent studies by Patel et al., 
(2008a and b) and Song and Kingston., (2008) demonstrate that WDR5 recognizes a conserved 
arginine containing motif in the N-SET region of MLL1 called the WDR5 interaction (Win) 
motif (Patel et al., 2008b), thereby promoting the assembly and the H3K4 dimethylation 
activity of the MLL1 core complex (Patel et al., 2008a; Patel et al., 2008b; Song and Kingston, 
2008) (Figure 6). Based on sedimentation velocity analytical ultracentrifugation experiments, 
Patel et al., (2008b) demonstrated that an MLL1 construct (encompassing residues 3745-3969) 
containing the highly conserved Win motif binds to WDR5 as a 1:1 complex with a dissociation 
constant of 120nM. Whereas, a shorter construct in MLL1 (encompassing residues 3811-3969) 
that lacks the Win motif sequence fails to associate with WDR5 (Patel et al., 2008b). In their 
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efforts to further map the interaction region between MLL1 and WDR5, the two groups 
showed that the conserved Win motif closely resembles the sequence surrounding arginine 2 
of histone H3 and is highly conserved among metazoan MLL1 orthologs and other SET1 
family members (Patel et al., 2008b; Song and Kingston, 2008) (Figure 6). Using a combination 
of analytical ultracentrifugation and MALDI-TOF mass spectrometry, it was demonstrated 
that the conserved arginine (R3765) of the MLL1 Win motif is crucial for the interaction with 
WDR5 and that substitution of R3765 with alanine in MLL1 abolishes the interaction between 
MLL1 and the WRAD sub-complex, which also results in the loss of the H3K4 dimethylation 
activity of the MLL1 core complex (Patel et al., 2008b). However, replacement of other residues 
such as serine 3763 and glutamate 3767 in the conserved Win motif sequence only modestly 
weakens MLL1’s interaction with the WRAD sub-complex (Patel et al., 2008b). Furthermore, 
the MLL1 R3765A mutant fails to co-immunoprecipitate the rest of the core complex 
components RbBP5 and Ash2L from HeLa cells, consistent with a central role for the MLL1 
Win motif in the assembly of MLL1 core complex in vivo (unpublished results from Lee and 
Skalnik).  These results have led to a model in which the conserved Win motif of MLL1 and 
other metazoan SET1 family members functions to bind the WDR5 component of the WDR5-
RbBP5-Ash2L sub-complex, which is required for the assembly and H3K4 dimethylation 
activity of the MLL1 core complex (Cosgrove and Patel, 2010; Trievel and Shilatifard, 2009). 
These observations suggest that targeting MLL1-WDR5 interaction might be an effective 
strategy to down-regulate H3K4 dimethylation and HOX gene expression mediated by the 
MLL1 core complex.   
 
 
Schematic representation of the Win motif present in SET1 family members. At the top the domain 
architecture of wild-type MLL1 is shown and color coded as in Figure 1. The six-residue Win motif is 
present within the N-SET region of MLL1 (amino acid residues 3762-3767). The lower inset (green) 
shows the ClustalW multiple sequence alignment of the Win motif present in human SET1 family 
members: MLL1 (Q03164), MLL2 (O14686), MLL3 (AAK00583), MLL4 (Q9UMN6), SET1a (O15047), and 
SET1b (Q9UPS6). The conserved arginine of the Win motif is highlighted in red.  
Fig. 6. WDR5 Interaction (Win) motif is highly conserved among human SET1 family 
members 
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6.4 Peptides derived from the MLL1 Win motif specifically inhibit the H3K4 
dimethylation activity of MLL1 core complex 
Based on mapping studies of the WDR5 binding region in MLL1, Patel et al., (2008b) 
developed a peptide, designated the MLL1 Win motif peptide (3762-3773) that can bind 
WDR5 with high affinity (Kd=1700nM) and disrupt the assembly of the MLL1 core complex 
in vitro (Patel et al., 2008a; Patel et al., 2008b). Consequently, this 12-residue MLL1 Win 
motif peptide inhibits the in vitro H3K4 dimethylation activity of the MLL1 core complex in 
a dose dependent manner by competing with wild-type MLL1 for the arginine binding 
pocket in WDR5 (Patel et al., 2008b). However, a control p53 peptide that has an arginine in 
a different sequence context failed to inhibit the H3K4 dimethylation activity even with a 60-
fold excess,  suggesting that Win motif peptides are highly specific inhibitors of MLL1 
family complexes (Patel et al., 2008b). Furthermore, recent unpublished results from our lab 
demonstrate that peptides derived from other human SET1 family members bind WDR5 
with dissociation constants ranging from 50nM-1700nM (in preparation). In accordance with 
the binding studies, MALDI-TOF mass spectrometry based methylation assays further 
demonstrate that other human SET1 family Win motif peptides are significantly more potent 
inhibitors of the H3K4 dimethylation activity of the MLL1 core complex as compared to the 
MLL1 Win motif peptide (Dharmarajan and Cosgrove, unpublished results). These studies 
suggest that the MLL1 Win motif based peptide represents an excellent starting point for the 
design of lead compounds that would specifically disrupt the interaction between MLL1 
and WDR5 and inhibit the H3K4 dimethylation activity of MLL1 core complex in vivo. 
6.5 MLL1 Win motif peptide binds to WDR5 by adopting a 310 –helical conformation 
Design of Win motif based inhibitors with better efficiency could be greatly enhanced by 
determining the protein structural features within the Win motif that are required for the 
high affinity binding to WDR5. To facilitate the process of structure-based drug design and 
to understand the molecular basis for MLL1-WDR5 interaction, two independent groups 
determined the three-dimensional structure of WDR5 bound to a peptide derived from the 
MLL1 Win motif (Patel et al., 2008a; Song and Kingston, 2008). The structures reveal that 
MLL1 Win motif peptide binds WDR5 by adopting a partial 310 -helical conformation (Figure 
7) (Patel et al., 2008a; Song and Kingston, 2008). The conserved Win motif residues (3762-
3767) all participate in the formation of 310–helix with two-intramolecular i->i+3 main-chain 
hydrogen bonds stabilizing this conformation (Figure 7). MLL1 Win peptide binding is 
further stabilized by the insertion of conserved R3765 of MLL1 into a central water filled 
tunnel of WDR5 (Patel et al., 2008a; Song and Kingston, 2008). The structures also 
demonstrate that the side chain guanidinium of R3765 is sandwiched between two aromatic 
rings from WDR5- residues Phe-133 and Phe-263. R3765 is also stabilized by an extensive 
network of hydrogen bond, pi-pi and cation-pi, and hydrophobic interactions (Patel et al., 
2008a; Song and Kingston, 2008) (Figure 7). These structural studies further corroborate the 
role of R3765 in mediating the interaction with WDR5 and explain the high sequence 
conservation of this arginine within SET1 family Win motifs. Accordingly, structures of 
WDR5 bound to Win motif peptides derived from other human SET1 family members reveal 
that WDR5 recognizes the different SET1 family Win motifs using the same arginine binding 
pocket as previously described for MLL1 (Dharmarajan and Cosgrove, unpublished results). 
However, the different Win motif peptides also participate in additional sets of interactions 
that might contribute to their differential inhibitory properties and suggest a framework for 
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the use of Win motif peptides as lead compounds for drug development (Dharmarajan and 
Cosgrove, unpublished results). While the Win peptide binding mode is similar to the 
previously determined structures of WDR5 bound to histone peptides, which bind by 
inserting R2 of histone H3 into the central tunnel in WDR5 (Couture et al., 2006; Han et al., 
2006; Schuetz et al., 2006), the SET1 family Win motif peptides participate in more favorable 
interactions with WDR5 (Patel et al., 2008a; Song and Kingston, 2008). These findings 
suggest that peptidomimetics based on the Win motif sequence can specifically bind WDR5 
and down-regulate the activity of MLL1 core complex.  
 
 
Three-dimensional structure of WDR5 (PDB code 3EG6) in complex with MLL1 Win motif peptide 
(3762-3773). a) On the left, the MLL1 Win motif peptide (cyan) is shown bound to the central tunnel in 
WDR5 (white). MLL1 Win motif peptide binds WDR5 by adopting a 310-helical conformation. On the 
right, blow up of the peptide binding site with MLL1 residues indicated in red and WDR5 residues 
indicated in black. Atom coloring: oxygen (red), nitrogen (blue), carbon (cyan for Win motif residues 
and grey for WDR5 residues).  
Fig. 7. Crystal structure of MLL1 Win motif peptide bound to WDR5 
6.6 Analysis of the binding of MLL1 Win motif and histone H3 peptides to WDR5: 
identification of key structural elements required for binding WDR5 
To facilitate the design of small-molecule inhibitors of MLL1-WDR5 interaction, Karatas et al 
(2010) performed a systematic deletion analysis on the original 12-residue MLL1 Win motif 
peptide (3762-3773) and showed that a three residue sequence composed of  Acetyl-ARA- NH2 is 
the minimal motif that is required for its interaction with WDR5 (Karatas et al., 2010). The 
acetyl group on the N-terminus is essential as its removal results in the loss of binding. 
The Acetyl-ARA-NH2 peptide binds WDR5 in peptide competition experiments with similar 
affinity to that of the original 12 residue MLL1 Win motif peptide (~120 nM) (Karatas et al., 
2010; Patel et al., 2008b). Moreover, systematic mutagenesis and molecular dynamics 
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simulations further suggest that Acetyl-ARA- NH2 peptide could recapitulate the two 
intramolecular i-> i+3 main chain hydrogen bonds that are present in the original 12-residue 
MLL1 Win motif peptide. Absence of one or both of these hydrogen bonds significantly 
weakens the interaction affinity between the 3-residue peptide and WDR5 (Karatas et al., 
2010). These results suggest that Acetyl-ARA-NH2 peptide binds WDR5 by adopting a partial 310 -
helical conformation similar to that of the 12-residue MLL1 Win motif peptide and participates 
in similar sets of interactions (Karatas et al., 2010; Patel et al., 2008b). However, the most potent 
inhibitor derived from the MLL1 Win motif peptide sequence is the acetyl-10mer (acetyl-
ARAEVHLRKS-NH2) encompassing residues 3764-3773, which binds WDR5 with a Ki = 3nM 
(Karatas et al., 2010). These results suggest that sequences outside of the ARA sequence 
contribute to the affinity and would likely increase specificity. In addition, replacement of 
alanine at the +1 position (1 residue C-terminal to R3765) with a threonine in the acetyl-10mer 
(acetyl-ARTEVHLRKS-NH2) or 3-mer (Acetyl-ART-NH2) results in a 3-to-6-fold increase in binding 
affinity to WDR5, respectively (Karatas et al., 2010). In summary, these experiments suggest 
that the Acetyl-ARA-NH2   motif anchors the peptide to the arginine binding pocket of WDR5 and 
that the 310 –helical conformation is crucial for interaction. In addition, sequences N- and C-
terminal to the ARA motif are important for increasing binding specificity. It remains to be 
determined if the Acetyl-ARA-NH2  peptide actually inhibits the WDR5-MLL1 interaction within 
the context of the assembled MLL1 core complex.  
6.7 Win motif based inhibitors - a novel class of compounds with potential to treat 
Acute Myeloid Leukemia 
The extensive biochemical characterization of the peptide derived from the MLL1 Win motif 
have demonstrated that these peptidomimetic compounds have the potential to inhibit the 
H3K4 methyltransferase activity of the MLL1 core complex by specifically disrupting the 
association of MLL1 with the WRAD sub-complex (Patel et al., 2008b). Furthermore, the 
crystal structures of WDR5 bound to human SET1 family Win motif  peptides provides a 
rationale for the design of new peptides and non-peptide mimetics with better inhibitory 
properties. The structures also reveal that conserved residues from the MLL1 Win motif 
(GSARAE) form a cyclical shaped 310 –helix that fits snugly into the outer opening in WDR5 
and raises the possibility that other cyclic peptidomimetic compounds might also bind 
WDR5 with similar or better inhibitory properties. The efficacy of Win motif based inhibitors 
in down regulating the H3K4 methylation activity of MLL1 core complex in vitro has yet to 
be demonstrated in vivo. However, based on the in vitro studies it is expected that the Win 
motif based peptides will have the ability to down regulate the increased H3K4 
dimethylation, and aberrant HOX gene expression associated with MLL1-PTDs and gene 
amplification mutations in MLL1. Hence, the MLL1 Win motif peptide is a novel “first in 
class” inhibitor that is expected to have the ability to specifically regulate H3K4 
dimethylation levels in cells without perturbing K3K4 monomethylation, or the methylation 
activities of other H3K4 methyltransferases.  
7. Conclusions and future perspectives - are there other molecular targets for 
leukemia therapy? 
Over the past decade, we have witnessed remarkable strides towards understanding the 
fundamental mechanisms of MLL1-mediated transcription and leukemogenesis, and many 
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targets that are likely to be biomedically important are beginning to be characterized (Dou 
and Hess, 2008; Liedtke and Cleary, 2009; Marschalek, 2010). Genetic, biochemical and 
structural studies have demonstrated that several MLL1 partner proteins (AF4, AF9, AF10, 
ENL, and EEN) are either directly or indirectly associated with macromolecular complexes 
involved in transcriptional initiation and elongation (Bitoun et al., 2007; Cheung et al., 2007; 
Marschalek; Mueller et al., 2007; Mueller et al., 2009; Okada et al., 2005; Okada et al., 2006). 
Based on these studies, it was also suggested that leukemogenic properties of these MLL1- 
fusions are mediated in part through their association with the histone methyltransferases: 
 
 
Cartoon representation of the different forms of MLL1 (a. wild-type, b. PTDs, and c. chromosomal 
translocations) and a summary of emerging potential molecular targeted therapies for mixed lineage 
leukemia. Key molecular targets include: i) inhibitors that disrupt the association of MLL1 with its 
target genes (MBM-based or CXXC motif-based inhibitors), ii) inhibitors that target the assembly of 
MLL1 core complex (Win motif-based inhibitors), iii) inhibitors that target the functions of fusion 
proteins (PFWT-like peptides, hDOT1L inhibitors, pTEFb kinase inhibitors), iv) WRAD sub-complex 
inhibitors and v) Inhibitors that target other co-operating pathways in leukemia (GSK-3, FLT3, MCL-1, 
and Ras). MLL-N (blue) and MLL-C (yellow) fragments are shown as localized to a hypothetical MLL1 
target gene. In a). menin (green), LEDGF (dark grey) and WRAD sub-complex associate with wild-type 
MLL1 to regulate the normal expression (indicated by a single arrow) of MLL1 target genes. Target gene 
expression is dysregulated in MLL1-PTDs and MLL1-fusions (b and c) as indicated by multiple arrows. 
b) MLL1-PTDs retain all the functional interactions as seen in wild-type MLL1 and c) MLL1-fusions do 
not retain the MLL-C fragment and many interacting proteins.. Figure 8 was adapted from Liedtke and 
Cleary (2009). 
Fig. 8. Potential protein:protein interaction targets for the development of novel therapies 
for MLL1-associated leukemias 
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hDOT1 (Bitoun et al., 2007; Okada et al., 2005; Okada et al., 2006) and protein arginine 
methyltransferase-1 or PRMT1 (Cheung et al., 2007). These studies have led to the proposal  
of the “MLL1 web hypothesis”, which states that MLL1 fusion partners are components of 
larger macromolecular complexes that are involved in transcriptional activation and/or 
elongation (Erfurth et al., 2004). Molecular therapies directed at the interactions of these 
proteins within the “MLL1 web hypothesis” or inhibiting the activity of associated histone 
modifying enzymes are emerging as promising targets (Dou and Hess, 2008; Liedtke and 
Cleary, 2009; Marschalek, 2010). In addition to targeting the function of MLL1-fusion 
proteins, inhibitors that target the association of MLL1-fusion proteins to target DNA might 
also have potential therapeutic implications. In this regard, inhibitors that disrupt the 
interaction between MLL1’s CXXC motif and unmethylated CpG containing target DNA are 
being investigated as molecular drug targets in MLL1-related leukemias (Allen et al., 2006; 
Cierpicki et al., 2010). In addition to these molecular targets, recent studies have also 
identified other cooperating pathways such as positive transcription elongation factor-b 
(pTEFb) recruitment (Marschalek, 2010; Mueller et al., 2007; Mueller et al., 2009; Shapiro, 
2006), activation of FMS-like tyrosine kinase 3 (FLT3) (Armstrong et al., 2003; Brown et al., 
2005; Stubbs et al., 2008; Yao et al., 2005), glycogen synthase kinase 3 (GSK3) (Wang et al., 
2008), heat shock protein-90 (HSP-90) (Yao et al., 2005; Yocum et al., 2006), myeloid cell 
leukemia sequence-1 (MCL-1) expression (Chen et al., 2009), and RAS pathways (Liang et 
al., 2006) that are implicated in MLL1-induced leukemogenesis. The therapeutic significance 
of these molecular targets in MLL1-therapy were reviewed recently (Dou and Hess, 2008; 
Liedtke and Cleary, 2009; Marschalek, 2010) and since then, additional potential 
pharmacological targets such as the multi-subunit complex WRAD, which regulates the 
degree of H3K4 methylation by the MLL1 core complex, have emerged (Patel et al., 2009; 
Patel et al., 2011) (Figure 8).   
In conclusion, this chapter summarizes recent biochemical studies that have contributed 
significantly to our understanding of how MLL1 works and have led to the identification of 
promising therapeutic targets for MLL1-related leukemias. In particular, inhibitors that 
target molecular interactions between menin and MLL1, AF4 and AF9, and MLL1 and 
WRAD have emerged as novel candidate small molecule targets. These MLL1-targeted 
therapies have enhanced pharmacological potential as compared to the existing broadly-
based chemotherapeutics for MLL1-associated leukemias and will hopefully result in better 
treatment outcomes. In the future, similar biochemical, structural and genetic studies will be 
instrumental in identifying additional molecular targets that will form the basis for novel 
treatment strategies.  
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